Washington,
D.C. 20549
FORM
6-K
REPORT
OF
FOREIGN ISSUER
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For
the month of April 2006
Commission
File Number 000-51122
pSivida
Limited
(Translation
of registrant’s name into English)
Level
12
BGC Centre
28
The
Esplanade
Perth
WA
6000
(Address
of principal executive offices)
(Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F).
Form
20-F
x Form
40-F o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):
Indicate
by check mark whether the registrant by furnishing the information contained
in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o No
x
If
"Yes"
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82- ___.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant,
pSivida Limited, has duly caused this report to be signed on its behalf by
the
undersigned, thereunto duly authorized.
| pSivida Limited | ||
| |
|
|
| Date: April 28, 2006 | By: | /s/ Aaron Finlay |
|
Aaron Finlay |
||
| Chief Financial Officer and Company Secretary | ||
EXHIBIT
INDEX
|
EXHIBIT
99.1:
|
pSivida
Quarterly Cashflow - March 2006 Commentary and
Highlights
|
|
EXHIBIT
99.2:
|
Appendix
4C
|
-2-
 |
|
| ASX/Media RELEASE |
28
April 2006
|
pSivida
Quarterly Cashflow - March 2006
Commentary
and Highlights
RetisertTM
royalties rising, as sales increase
Cost
savings from acquisition
Global
bio-nanotech company pSivida Limited is pleased to release its quarterly
cashflow statement for the period ending the 31st
of
March, 2006.
Following
the acquisition of pSivida Inc. (formerly Control Delivery Systems Inc.) on
the
30th
of
December, 2005, the March quarter is the first whole quarter that includes
the
results of the recently acquired US business.
It
is
important to note that the net operating cash outflow for the quarter has been
limited to AU$4.8 million, an increase of AU$203,000 or 4.4% when compared
the
previous quarter. Despite this increase, cash outflows were mitigated as a
result of cost synergies being realised between the two companies, a review
of
costs being undertaken and implemented during the period and the receipt of
payments from collaborative partners and Retisert™
royalties. Cost synergies from the merger are continuing to be pursued with
greater use to be made of our Boston facilities.
Retisert™
royalties that would have otherwise been earned from launch in the United States
in the second half of 2005 to the 31st
of
March, 2006 totalled AU$1.25 million (US$894,144). It should be noted,
however that this amount is reduced by 50% in accordance with an advance royalty
agreement Control Delivery Systems entered into with Bausch & Lomb in June
2005 and we refer you to a detailed analysis of Retisert™
royalties within the Appendix 4C.
In
February, Bausch & Lomb appointed global pharmaceutical company, Novartis to
co-promote Retisert™ for uveitis in the United States, significantly increasing
the number of sales representatives dedicated to the promotion of
Retisert™.
Post
Quarter Highlights and Announcements
BrachySil™
clinical development programmes progress
The
clinical development of pSivida’s targeted oncology product has progressed with
further recruitment into the ongoing multicentre phase IIb trial in primary
liver cancer. The clinical programme for pancreatic cancer progressed with
the critical regulatory agency clinical trial applications filed with European
and Asian agencies as the prerequisite for treatment of the first patients
in
this second indication of high unmet medical need.
Positive
European trial results for Retisert™
for Uveitis
Two
year
results from Bausch & Lomb’s European clinical trial of Retisert™
for the
treatment of chronic non-infectious posterior
segment uveitis showed
the
recurrence rate for uveitis was significantly lower in
eyes
receiving Retisert™
than in
eyes receiving standard of care (systemic
corticosteroid or other immunosuppressive agents).
The
study involved 146 patients across ten countries in Europe and the Middle East.
These results were presented at the prestigious
6th
International Symposium on Ocular Pharmacology and Therapeutics in Berlin that
commenced on the 30th
of
March, 2006.
pSivida
signs new evaluation agreements for cardiovascular drug
delivery
pSivida
entered into an evaluation agreement with an undisclosed large medical device
company to evaluate cardiovascular
delivery of drugs using pSivida’s drug delivery technologies. The
agreement
demonstrated that pSivida’s drug delivery technologies are being evaluated in
areas beyond ophthalmology and oncology treatments
and
follows
recent announcements that pSivida had signed evaluation agreements with
various companies, including large global pharmaceutical companies, to evaluate
pSivida’s proprietary platform technology for their developmental compounds.
pSivida has licensing agreements with Bausch & Lomb, Alimera Sciences and
Beijing Med-Pharm and evaluation agreements with three of the five largest
pharmaceutical companies in the world.
In
non-core areas, pSivida has signed two new material evaluation agreements this
year for BioSilicon™
to be
incorporated into devices with larger US based companies.
Retisert™
slows progression of Diabetic Retinopathy in DME trials
Additional
two year trial results of Bausch & Lomb’s two randomized trials to evaluate
the safety and efficacy of the Retisert™
implant
in releasing fluocinolone acetonide in the management of Diabetic Macular Edema
(DME) demonstrated that 30% of eyes receiving standard of care (repeat laser
treatment) had a worsening of their Diabetic Retinopathy compared with only
10%
of eyes receiving a Retisert™
implant.
This was statistically significant. Retisert™
also
reduced retinal thickening involving the fovea (the centre most part of the
macula responsible for sharp, central vision) and led to a statistically
significant three line improvement in vision. The trial results were presented
at the prestigious 6th
International Symposium on Ocular Pharmacology and Therapeutics in Berlin that
commenced on the 30th
of
March, 2006.
Highlights
and Announcements for the Quarter
DSMB
recommends continuation of Medidur™
Phase III clinical trial
Following
a planned interim review, a Data Safety Monitoring Board (DSMB) recommended
the
continuation of its Phase III clinical trial of Medidur™ following a meeting on
March 16, 2006 to review the Medidur™ Phase III clinical trial data. Medidur™, a
tiny injectable device, is being studied as a way to deliver fluocinolone
acetonide, a corticosteroid, to the retina for up to three years as a treatment
for diabetic macular edema (DME). After reviewing the preliminary safety data
from the initial US patients enrolled in the Medidur™ trial, the DSMB agreed
that enrolment should accelerate in the Phase III trial under the current
protocol. The DSMB provides independent evaluation of study data to identify
potential safety issues that might warrant modification or early termination
of
ongoing studies.
Medidur™ manufacture
certified to be GMP equivalent to EU standards
Following
an independent audit of its Boston, Massachusetts facility by a European
Qualified Person (QP), the QP issued a certificate that Medidur™
is
manufactured to a standard of Good Manufacturing Practice (GMP) equivalent
to
that in the European Union, as set out in directive 2003/94/EC and the EC Guide
to GMP.
pSivida
added to new Nanotechnology Index
pSivida
has been included in a new nanotechnology index established by The Nanotech
Company, LLC, of San Diego, California. The Nanotechnology.com ‘Small
Technology’ Index is composed of 30 of the leading, international,
publicly-traded companies and is designed to mimic the portfolio of a
sophisticated fund manager with US$30 million to place in the area of small
tech
and nanotechnology. The index is diversified by geography, industry sector,
type
of small tech, market capitalization and other criteria and does not include
Fortune 500 companies with relatively insignificant small tech product revenue.
Rather, the index focuses on companies that are primarily involved in the
nanotech space, such as pSivida.
Diabetic
Macular Edema trial with Retisert™
Preliminary
three year follow-up data from Bausch
& Lomb’s
multi-center, randomized, controlled clinical trial of Retisert™
for the
treatment of diabetic macular edema (DME)
showed
that significantly more patients receiving a Retisert™
implant
had improved visual acuity (of three or more lines on an eye chart) than those
receiving standard of care.
Uveitis
long term trial results positive for pSivida
Preliminary
three year follow-up data from Bausch
& Lomb’s
multi-center, randomized, dose-masked clinical trial of Retisert™
for the
treatment of chronic non-infectious posterior
segment uveitis showed
that the recurrence rate was significantly lower in
eyes
receiving Retisert™
than in
non-implanted eyes. This study involved 278 patients from 27 hospitals in the
United States and one in Singapore.
Novartis
to co-promote Retisert™
with Bausch & Lomb
Retisert™,
developed by pSivida, is the world’s first intravitreal drug implant for the
treatment of chronic noninfectious posterior segment uveitis, a sight
threatening condition that affects an estimated 175,000 people in the United
States and an estimated 800,000 people worldwide. Licensed to Bausch & Lomb,
pSivida receives royalties on Retisert™
sales
with the collaboration with Novartis expanding the dedicated sales force of
Retisert™
in the
United States.
Several
new Pharma agreements for pSivida Inc.
Wholly
owned subsidiary pSivida Inc. entered
into a number of new evaluation agreements with various companies, including
large global pharmaceutical companies, to evaluate pSivida’s proprietary
platform technology for their developmental compounds. The
terms
of the new evaluation agreements vary,
but
are typically 12 months in duration with the costs being borne by the
counterparty.
Acquisition
of Control Delivery Systems
pSivida
completed the acquisition of Boston based private drug delivery company
Control
Delivery Systems (CDS), following overwhelming approval by pSivida shareholders
at the AGM held in November 2005. The
acquisition is an integral part of pSivida’s on-going US growth strategy.
CDS’
portfolio of products and product candidates includes two approved and marketed
products, one Phase III product and other early-stage product candidates.
Australian publication Bioshares announced pSivida’s acquisition of CDS as the
‘Biotech M&A Deal of the Year’, citing pSivida’s increased presence in the
US, current revenue stream and synergies for combining the two companies’
technologies and expertise.
CDS was
renamed pSivida Inc. and former CEO, Dr. Paul Ashton has been appointed to
the
pSivida Board and is now the Director of Strategy, based in Boston.
Non-executive
Director appointed
Ms.
Heather Zampatti has been appointed as a Non-executive Director of the Company,
based in Perth, Australia. Ms.
Zampatti is the National Head of Wealth Management, Australia for Bell Potter
Securities, an Australian-owned private investment adviser and Top 10 broker
by
trading volume on the Australian Stock Exchange. Ms. Zampatti has over 20 years
experience in investment advising and her expertise in stockbroking and
financial investment planning is widely acknowledged in the Australian
investment community. The appointment of Ms. Zampatti to the pSivida Board
replaces Ms. Alison Ledger who has stepped down after 18 months of service
to
focus on new career initiatives. We thank Alison for her valuable contribution
and wish her well in her future endeavours.
-ENDS-
Released
by:
|
pSivida
Limited
Brian
Leedman
Investor
Relations
pSivida
Limited
Tel:
+ 61 8 9226 5099
brianl@psivida.com
|
US
Public Relations
Beverly
Jedynak
President
Martin
E. Janis & Company, Inc
Tel:
+1 (312) 943 1100 ext. 12
bjedynak@janispr.com
|
UK
& Europe Public Relations
Mark
Swallow / Helena Podd
Citigate
Dewe Rogerson
Tel:
+44 (0)20 7638 9571
mark.swallow@citigatedr.co.uk
|
NOTES
TO EDITORS:
pSivida
is a global bio-nanotech company committed to the biomedical sector and the
development of drug delivery products. Retisert™ is FDA approved for the
treatment of uveitis. Vitrasert® is FDA
approved
for the treatment of AIDS-related CMV Retinitis. Bausch & Lomb own the
trademarks; Vitrasert® and Retisert™. pSivida has licensed the technologies
underlying both of these products to Bausch & Lomb. The technology
underlying Medidur™, a treatment for diabetic macular edema, is licensed to
Alimera Sciences and is in Phase III clinical trials.
pSivida
owns the rights to develop and commercialise a modified form of silicon
(porosified or nano-structured silicon) known as BioSilicon™, which has
applications in drug delivery, wound healing, orthopaedics, and tissue
engineering. pSivida’s subsidiary, AION Diagnostics Limited is developing
diagnostic products and the subsidiary pSiNutria is developing food technology
products both using BioSilicon™.
pSivida’s
intellectual property portfolio consists of 70 patent families, 74 granted
patents and over 290 patent applications.
pSivida
conducts its operations from offices and facilities near Boston in the United
States, Malvern in the United Kingdom, Perth in Western Australia and Singapore.
pSivida
is listed on NASDAQ (PSDV),
the
Australian Stock Exchange (PSD)
and in
Germany on the Frankfurt Stock Exchange on the XETRA system (German Symbol:
PSI. Securities Code (WKN) 358705).
pSivida is a founding member of the NASDAQ Health Care Index and the Merrill
Lynch Nanotechnology Index.
The
Company's largest shareholder and a strategic partner is QinetiQ, a leading
international defence, security and technology company, formed in 2001 from
the
UK Government's Defence Evaluation & Research Agency (DERA). QinetiQ
was instrumental in discovering BioSilicon™
and
pSivida enjoys a strong relationship with it having access to its cutting edge
research and development facilities. For more information visit www.QinetiQ.com
For
more
information, visit www.psivida.com
This
document contains forward-looking statements that involve risks and
uncertainties. The statements are indicated by the use of words such as
"believes", "expects", "anticipates" and similar words and phrases.
Although we believe that the expectations reflected in such forward-looking
statements are reasonable at this time, we can give no assurance that such
expectations will prove to be correct. Given these uncertainties, readers are
cautioned not to place undue reliance on such forward-looking statements. Actual
results could differ materially from those anticipated in these forward-looking
statements due to many important factors including: the failure of the results
of the Retisert for DME trial to be a good indicator of
the
results of pSivida’s ongoing Phase III
Medidur™
for DME trial; failure of the
Medidur™
trials
in DME to show a very similar improvement in visual acuity and diabetic
retinopathy severity score as Retisert™
for
DME;
inability to recruit patients for the Phase
III
Medidur™
for DME trial; our failure to develop applications for BioSilicon™
due to
regulatory, scientific or other issues, our inability to successfully integrate
pSivida Inc’s operations and employees; the failure of the pSivida Inc’s
products to achieve expected revenues and the combined entity’s inability to
develop existing or proposed products; the failure of the Bausch &
Lomb/Novartis co-promotion arrangement to provide faster royalty growth; failure
of the slower progression or reduction of diabetic retinopathy resulting from
the Retisert™ implant to have significant implications for Retisert™ and
Medidur; failure of our evaluation agreements to result in license agreements;
failure of Medidur™ to release the same drug as Retisert™ at the same rate;
failure of the
Medidur™
trials
in DME to show a very similar stabilization or improvement diabetic retinopathy
as Retisert™
for
DME;
failure
to achieve cost savings.
Other
reasons are contained in cautionary statements in the Annual Report on Form
20-F
filed with the U.S. Securities and Exchange Commission, including, without
limitation, under Item 3.D, "Risk Factors" therein. We do not undertake to
update any oral or written forward-looking statements that may be made by or
on
behalf of pSivida.
Appendix
4C
Quarterly
report for entities
admitted
on the basis of commitments
Rule
4.7B
Appendix
4C
Quarterly
report
for
entities admitted
on
the basis of commitments
Introduced
31/3/2000. Amended 30/9/2001
|
Name
of entity
|
|
pSivida
Limited
|
|
ABN
|
Quarter
ended (“current quarter”)
|
|
|
78
009 232 026
|
31
March 2006
|
Consolidated
statement of cash flows
|
Cash
flows related to operating activities
|
Current
quarter
$A’000 |
Year
to date
(9
months)
$A’000
|
|
|
1.1
|
Receipts
from customers
|
1,014
|
1,014
|
|
1.2
|
Payments
for (a)
staff costs
|
(327)
|
(1,119)
|
|
(b)
advertising and marketing
|
-
|
-
|
|
|
(c)
research and development
|
(3,174)
|
(8,434)
|
|
|
(d)
leased assets
|
-
|
-
|
|
|
(e)
other working capital
|
(1,956)
|
(5,421)
|
|
|
1.3
|
Dividends
received
|
-
|
-
|
|
1.4
|
Interest
and other items of a similar nature received
|
182
|
428
|
|
1.5
|
Interest
and other costs of finance paid
|
(634)
|
(635)
|
|
1.6
|
Income
taxes paid
|
-
|
-
|
|
1.7
|
Other
- other income
|
26
|
68
|
|
-
income received in advance
|
-
|
494
|
|
|
Net
operating cash flows
|
(4,869)
|
(13,605)
|
|
+ See chapter 19 for defined terms.
Appendix
4C Page 1
Appendix
4C
Quarterly
report for entities
admitted
on the basis of commitments
|
Current
quarter
$A’000
|
Year
to date
(9
months)
$A’000
|
||
|
1.8
|
Net
operating cash flows (carried forward)
|
(4,869)
|
(13,605)
|
|
Cash
flows related to investing activities
|
|||
|
1.9
|
Payment
for acquisition of:
|
||
|
(a)
businesses (item 5)
|
-
|
-
|
|
|
(b)
equity investments
|
(3,561)
|
(4,647)
|
|
|
(c)
intellectual property
|
-
|
-
|
|
|
(d)
physical non-current assets
|
(201)
|
(979)
|
|
|
(e)
other non-current assets
|
-
|
-
|
|
|
1.10
|
Proceeds
from disposal of:
|
||
|
(a)
businesses (item 5)
|
-
|
-
|
|
|
(b)
equity investments
|
-
|
-
|
|
|
(c)
intellectual property
|
-
|
-
|
|
|
(d)
physical non-current assets
|
-
|
-
|
|
|
(e)
other non-current assets
|
-
|
-
|
|
|
1.11
|
Loans
to other entities
|
-
|
-
|
|
1.12
|
Loans
repaid by other entities
|
-
|
-
|
|
1.13
|
Other
- costs of acquisition not capitalised
|
(1,868)
|
(1,868)
|
|
Net
investing cash flows
|
(5,630)
|
(7,494)
|
|
|
1.14
|
Total
operating and investing cash flows
|
(10,499)
|
(21,099)
|
|
Cash
flows related to financing activities
|
|||
|
1.15
|
Proceeds
from issues of shares, options, etc.
|
-
|
5,636
|
|
1.16
|
Proceeds
from sale of forfeited shares
|
-
|
-
|
|
1.17
|
Proceeds
from borrowings
|
-
|
19,927
|
|
1.18
|
Repayment
of borrowings
|
-
|
-
|
|
1.19
|
Dividends
paid
|
-
|
-
|
|
1.20
|
Other -
share issue costs
|
-
|
(469)
|
|
-
other financing costs
|
(59)
|
(92)
|
|
|
Net
financing cash flows
|
(59)
|
25,002
|
|
|
Net
increase (decrease) in cash held
|
(10,558)
|
3,903
|
|
|
1.21
|
Cash
at beginning of quarter/year to date
|
27,683
|
12,892
|
|
1.22
|
Exchange
rate adjustments to item 1.20
|
259
|
589
|
|
1.23
|
Cash
at end of quarter
|
17,384
|
17,384
|
+
See chapter 19 for defined terms.
Appendix
4C Page 2
Appendix
4C
Quarterly
report for entities
admitted
on the basis of commitments
Payments
to directors of the entity and associates of the directors
Payments
to related entities of the entity and associates of the related
entities
|
Current
quarter
$A'000
|
||
|
1.24
|
Aggregate
amount of payments to the parties included in item 1.2
|
271
|
|
1.25
|
Aggregate
amount of loans to the parties included in item 1.11
|
-
|
|
1.26
|
Explanation
necessary for an understanding of the transactions
|
|
|
1.1
Royalty
revenues otherwise payable to the Company under the Bausch & Lomb
licence agreement for the sale of Retisert for the first calendar
quarter
amounted to approximately $474,000 (US$338,720). It should be noted,
however that this amount is reduced by 50% to $237,000 (US$169,360)
in
accordance with an agreement CDS entered into with Bausch & Lomb in
June 2005. Under this agreement, CDS received US$3 million from Bausch
& Lomb as an advance payment in lieu of US$6.25 million of future
royalties that would otherwise be payable to CDS. Under the terms
of the
related agreement, the royalty payable will be reduced as follows:
Bausch
& Lomb will retain 50% of the first US$3 million of royalties or
US$1.5 million; and 100% of the next US$4.75 million or royalties.
Since
this advance is non refundable, other than as an offset to future
royalties receivable by CDS and there are no future performance
obligations by CDS, the full US$3 million was reflected by CDS as
royalty
revenue in the month of June 2005. On the basis that the acquisition
of
CDS completed on 30 December, 2005 the CDS results will be consolidated
from this date. As
a result of the Bausch & Lomb agreement, pSivida will record as
revenues 50% of the royalty revenue that is otherwise payable by
Bausch
and Lomb for the first US$3 million of royalties and will record
no
royalty revenue on the next US$4.75 million of royalty revenue that
is
otherwise payable. After cumulative royalties otherwise payable
reach a total of US$6.25 million,
pSivida will record the full amount of
subsequent
royalties as royalty income in its consolidated financial
statements.
1.2(a) Staff
costs include consultants and directors’ fees paid by
pSivida.
1.2(c) Research
and development costs include all expenditure incurred by pSiMedica
and
pSiOncology.
|
||
Non-cash
financing and investing activities
|
2.1
|
Details
of financing and investing transactions which have had a material
effect
on consolidated assets and liabilities but did not involve cash
flows
|
|
N/A
|
|
2.2
|
Details
of outlays made by other entities to establish or increase their
share in
businesses in which the reporting entity has an
interest
|
|
N/A
|
+ See chapter 19 for defined terms.
Appendix
4C Page 3
Appendix
4C
Quarterly
report for entities
admitted
on the basis of commitments
Financing
facilities available
Add
notes as necessary for an understanding of the position. (See AASB 1026
paragraph 12.2).
|
Amount
available
$A’000
|
Amount
used
$A’000
|
||
|
3.1
|
Loan
facilities
|
-
|
21,097
|
|
3.2
|
Credit
standby arrangements
|
-
|
-
|
Reconciliation
of cash
|
Reconciliation
of cash at the end of the quarter (as shown in the
consolidated statement of cash flows) to the related items in the accounts is as follows. |
Current
quarter
$A’000
|
Previous
quarter
$A’000
|
|
|
4.1
|
Cash
on hand and at bank
|
4,685
|
2,406
|
|
4.2
|
Deposits
at call
|
12,699
|
25,277
|
|
4.3
|
Bank
overdraft
|
-
|
-
|
|
4.4
|
Other
(provide details)
|
-
|
-
|
|
Total:
cash at end of quarter (item
1.22)
|
17,384
|
27,683
|
|
Acquisitions
and disposals of business entities
|
Acquisitions
(Item
1.9(a))
|
Disposals
(Item
1.10(a))
|
||
|
5.1
|
Name
of entity
|
N/A
|
N/A
|
|
5.2
|
Place
of incorporation or registration
|
||
|
5.3
|
Consideration
for
acquisition
or disposal
|
||
|
5.4
|
Total
net assets
|
||
|
5.5
|
Nature
of business
|
||
+ See chapter 19 for defined terms.
Appendix
4C Page 4
Appendix
4C
Quarterly
report for entities
admitted
on the basis of commitments
Compliance
statement
|
1
|
This
statement has been prepared under accounting policies which comply
with
accounting standards as defined in the Corporations Act (except to
the
extent that information is not required because of note 2) or other
standards acceptable to ASX.
|
|
2
|
This
statement does give a true and fair view of the matters
disclosed.
|
| Sign here: |
Date:
28 April 2006
|
|
|
(Company
secretary)
|
||
| Print name: | Aaron Finlay |
Notes
| 1. |
The
quarterly report provides a basis for informing the market how the
entity’s activities have been financed for the past quarter and the effect
on its cash position. An entity wanting to disclose additional information
is encouraged to do so, in a note or notes attached to this
report.
|
| 2. |
The
definitions in, and provisions of, AASB
107: Cash Flow Statements
apply to this report except for the paragraphs of the Standard set
out
below.
|
| · |
6.2 -
reconciliation of cash flows arising from operating activities to
operating
profit or loss
|
| · |
9.2 -
itemised disclosure relating to
acquisitions
|
| · |
9.4 -
itemised disclosure relating to
disposals
|
| · |
12.1(a) -
policy for classification of cash
items
|
| · |
12.3 -
disclosure of restrictions on use of
cash
|
| · |
13.1 -
comparative information
|
| 3. |
Accounting
Standards. ASX
will accept, for example, the use of International Accounting Standards
for foreign entities. If the standards used do not address a topic,
the
Australian standard on that topic (if any) must be complied
with.
|
+
See chapter 19 for defined terms.
Appendix
4C Page 5